Vertex Pharmaceuticals Target Price

See Vertex Pharmaceuticals's analyst price targets ($540) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$477.1

Average Target Price

$536.50

12.5% upside

12 analysts in the last 4 months

High: $616 | Low: $350

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-13	UBS	$585	22.6% upside
2026-07-13	Truist Financial	$560	17.4% upside
2026-07-07	RBC Capital	$570	19.5% upside
2026-07-07	Robert W. Baird	$350	26.6% downside
2026-05-27	Truist FinancialDanielle Brill	$542	13.6% upside
2026-05-06	Barclays	$615	28.9% upside
2026-05-05	Morgan Stanley	$616	29.1% upside
2026-05-05	RBC CapitalBrian Abrahams	$543	13.8% upside
2026-05-05	Bernstein	$572	19.9% upside
2026-05-05	Canaccord Genuity	$436	8.6% downside
2026-04-30	Canaccord Genuity	$437	8.4% downside
2026-04-10	Morgan Stanley	$612	28.3% upside
2026-03-10	Truist FinancialJoon Lee	$525	10% upside
2026-03-10	JefferiesAkash Tewari	$580	21.6% upside
2026-03-02	BMO CapitalEvan David Seigerman	$600	25.8% upside
2026-02-17	Canaccord Genuity	$441	7.6% downside
2026-02-17	BarclaysEliana Merle	$607	27.2% upside
2026-02-17	H.C. WainwrightAndrew Fein	$591	23.9% upside
2026-02-13	Morgan StanleyTerence Flynn	$570	19.5% upside
2026-02-13	ScotiabankLouise Chen	$558	17% upside
2026-02-13	RBC Capital	$541	13.4% upside
2026-02-13	Bernstein	$577	20.9% upside
2026-02-13	Cantor Fitzgerald	$590	23.7% upside
2026-02-13	Stifel NicolausPaul Matteis	$466	2.3% downside
2026-02-13	H.C. WainwrightAndrew Fein	$518	8.6% upside
2026-01-27	Barclays	$606	27% upside
2026-01-26	UBS	$545	14.2% upside
2026-01-23	Evercore ISICory Kasimov	$530	11.1% upside
2026-01-22	RBC CapitalBrian Abrahams	$546	14.4% upside
2026-01-06	UBSMichael Yee	$535	12.1% upside
2025-12-29	Leerink Partners	$525	10% upside
2025-12-05	Morgan Stanley	$564	18.2% upside
2025-12-03	Morgan StanleyTerence Flynn	$516	8.2% upside
2025-11-04	RBC Capital	$415	13% downside
2025-11-04	Cantor FitzgeraldCarter Gould	$485	1.7% upside
2025-11-04	Stifel Nicolaus	$445	6.7% downside
2025-11-04	BarclaysGena Wang	$414	13.2% downside
2025-10-10	Morgan Stanley	$438	8.2% downside
2025-09-25	Leerink Partners	$456	4.4% downside
2025-08-05	Truist Financial	$490	2.7% upside
2025-08-05	Stifel Nicolaus	$455	4.6% downside
2025-08-05	UBSEliana Merle	$553	15.9% upside
2025-08-05	BMO Capital	$530	11.1% upside
2025-08-05	H.C. Wainwright	$478	0.2% upside
2025-08-05	Morgan Stanley	$439	8% downside
2025-06-17	RBC CapitalBrian Abrahams	$420	12% downside
2025-05-06	ScotiabankGreg Harrison	$442	7.4% downside
2025-04-22	Cantor Fitzgerald	$535	12.1% upside
2025-01-31	BMO CapitalEvan Seigerman	$545	14.2% upside
2025-01-30	Wells FargoMohit Bansal	$460	3.6% downside

Vertex Pharmaceuticals (VRTX) FAQ

Vertex Pharmaceuticals (VRTX) currently reports a target price of $540. Use the charts on this page to explore Vertex Pharmaceuticals's target price history and peer comparisons.

Analysts' average 12-month price target for Vertex Pharmaceuticals is $540, about 12.5% upside from the current share price of $477.1. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $540, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Vertex Pharmaceuticals, and consider following VRTX for alerts when major investors trade the stock.

Vertex Pharmaceuticals is classified in the Healthcare sector. On target price, it currently shows $540. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VRTX with unrelated industries.